Ingredients supplier Gencor recently announced positive topline results for its Gynostemma pentaphyllum extract, ActivAmp, in a body composition study which involved overweight male and female participants. The study, which evaluated overweight “class one” obese subjects over 18 years old, found that 16 weeks of supplementation with a daily dose of 450 mg of the extract resulted in significant reductions of visceral fat in men, along with significant reductions in gynoid fat in women, compared to a placebo group.
 
“We are extremely pleased with our clinically meaningful study results on body composition,” said Chase Shyroc, Vice President of Sales & Business Development for Gencor. “In previous human, animal and phytochemical studies, ActivAMP has achieved a demonstrated effect on the metabolic process via AMPk activation. This recent study provides additional validation for Gencor’s weight management platform.”
 
In the study, the 450 mg of ActivAMP was divided into two capsules, one taken with water at breakfast, and the second taken with dinner for a period of 16 weeks. The primary outcome was measured by body fat via a dual-energy X-ray absorptiometry scan.
 
According to the World Health Organization, the global increase in overweight adults and children is caused by an increased intake of energy-dense foods, as well as a decrease in physical activity resulting from a variety of factors such as localization of work, urbanization, and greater accessibility of transportation, among others.
 
“Given the changes in both dietary and physical activity patterns of our society, we must continue to research methods of complementing lifestyle modifications, such as diet and exercise. Gynostemma pentaphyllum has long been studied as a tool for management of healthy body composition because of its ability to reduce lipid and blood glucose levels,” Shyroc said.  
 
ActivAMP is available in powder form, which can then be utilized either in its existing form, or as a tablet or capsule.